Rhumbline Advisers Trims Stock Position in Xencor, Inc. $XNCR

Rhumbline Advisers lowered its stake in shares of Xencor, Inc. (NASDAQ:XNCR) by 3.6% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 163,857 shares of the biopharmaceutical company’s stock after selling 6,143 shares during the period. Rhumbline Advisers owned about 0.23% of Xencor worth $1,743,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the stock. New York State Teachers Retirement System raised its stake in shares of Xencor by 2.1% during the 1st quarter. New York State Teachers Retirement System now owns 59,326 shares of the biopharmaceutical company’s stock valued at $631,000 after buying an additional 1,200 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Xencor during the 4th quarter valued at about $34,000. Exchange Traded Concepts LLC grew its position in shares of Xencor by 23.9% during the 1st quarter. Exchange Traded Concepts LLC now owns 9,814 shares of the biopharmaceutical company’s stock valued at $104,000 after acquiring an additional 1,896 shares during the period. CWM LLC raised its holdings in Xencor by 195.5% in the 1st quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 2,231 shares during the period. Finally, Wellington Management Group LLP boosted its position in Xencor by 8.3% during the first quarter. Wellington Management Group LLP now owns 29,776 shares of the biopharmaceutical company’s stock worth $317,000 after purchasing an additional 2,285 shares in the last quarter.

Analyst Ratings Changes

A number of equities analysts have issued reports on XNCR shares. Royal Bank Of Canada lowered their price target on Xencor from $32.00 to $15.00 and set an “outperform” rating on the stock in a research report on Thursday, August 21st. Wedbush reiterated an “outperform” rating and set a $26.00 price target on shares of Xencor in a research report on Tuesday, September 2nd. Wells Fargo & Company lowered their price target on Xencor from $33.00 to $27.00 and set an “overweight” rating on the stock in a research report on Thursday, August 7th. Bank of America downgraded Xencor from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $23.00 to $12.00 in a research report on Wednesday, September 3rd. Finally, Barclays started coverage on Xencor in a research report on Wednesday. They set an “underweight” rating and a $6.00 price target on the stock. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $22.25.

Xencor Trading Up 8.4%

XNCR stock opened at $10.03 on Friday. Xencor, Inc. has a 12-month low of $6.92 and a 12-month high of $27.24. The stock has a market cap of $715.37 million, a price-to-earnings ratio of -4.18 and a beta of 0.82. The business’s 50-day moving average is $8.35 and its 200 day moving average is $9.24.

Xencor (NASDAQ:XNCR) last issued its earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.37. The business had revenue of $43.61 million for the quarter, compared to analysts’ expectations of $22.59 million. Xencor had a negative return on equity of 25.75% and a negative net margin of 121.52%.The business’s revenue for the quarter was up 82.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.07) EPS. As a group, equities analysts forecast that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.